drugset / Trial / NCT05357794

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794

Phase 2 Recruiting 30 enrolled M.D. Anderson Cancer Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides

Timeline

Start
2022-10-13
Primary completion
2027-01-30
Completion
2027-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brentuximab Vedotin Monoclonal antibody Intravenous

Indications